Oral Session

Oral Session 1-14A Immune Cell Therapy Using iPS Cells

Fri. Oct 11, 2019 9:00 AM - 10:00 AM No.14 (Tokyo International Forum, 6F G610)

Chair: Miki Ando (Department of Hematology, Juntendo University School of Medicine)

+Add all to schedule

[OS1-14A-1] Genetically engineered progenitor cells from human iPSCs enable the robust production of neutrophils

Masashi Miyauchi¹, Fumi Nakamura¹, Yusuke Ito¹, Yuki Iwasaki², Taiki Kawagoshi², Yuki Kagoya³, Shunya Arai¹, Mineo Kurokawa^1,3 (1.Hematol., Tokyo Univ., Tokyo, Japan, 2.Kyowa Hakko Kirin Co. Ltd., Research and Developmen, Tokyo, Japan, 3.Dept. Cell Therapy and Transplantation Medicine, Tokyo Univ., Tokyo, Japan)

[OS1-14A-2] iPSC-derived CTL therapy for cervical cancer by targeting human papillomavirus (HPV)

Tadahiro Honda¹, Miki Ando^1,2, Yumi Sakiyama^1,2, Midori Ishii¹, Sakiko Harada¹, Kazuo Ohara¹, Jun Ando¹, Hiromitsu Nakauchi^2,3, Norio Komatsu¹ (1.Department of Hematology, Juntendo University School of Medicine, 2.Division of Stem Cell Therapy, IMSUT, Tokyo, 3.Institute for Stem Cell Biology and Regenerative Medicine, Stanford University)

[OS1-14A-3] Advanced precision medicine using iPS cell-derived dendritic cells for cancer therapy modeling

Shigetaka Shimodaira, Terutsugu Koya, Takuya Sakamoto, Misa Togi, Tomohisa Kato (Regenerative Med., Kanazawa Med. Univ., Ishikawa, Japan)

[OS1-14A-4] The neoantigen-specific iPSC-derived rejuvenated CTL therapy for Ewing sarcoma

Midori Ishii^1,2, Miki Ando^1,3, Yumi Sakiyama^1,3, Sakiko Harada¹, Tadahiro Honda¹, Jun Ando¹, Norio Komatsu¹, Hiromitsu Nakauchi^3,4 (1.Department of Hematology, Juntendo University School of Medicine, 2.Department of Orthopedic Surgery, Juntendo University School of Medicine, 3.Division of Stem Cell Therapy, IMSUT, Tokyo, 4.Institute for Stem Cell Biology and Regenerative Medicine, Stanford University)

[OS1-14A-5] Development of iPS cell derived LMP1-CART therapy for refractory EB virus associated lymphomas

Sakiko Harada¹, Miki Ando^1,2, Jun Ando¹, Satoshi Yamasaki², Midori Ishii¹, Tadahiro Honda¹, Kazuo Ohara¹, Yumi Sakiyama¹, Yozo Nakazawa³, Malcolm K. Brenner⁴, Hiromitsu Nakauchi^2,5, Norio Komatsu¹ (1.Department of Hematology, Juntendo University School of Medicine, 2.Division of Stem Cell Therapy, IMSUT, Tokyo, 3.Department of Pediatrics, Shinshu University School of Medicine, 4.CAGT, Baylor College of Medicine, TX, USA, 5.Institute for Stem Cell Biology and Regenerative Medicine, Stanford University)

[OS1-14A-6] Measles virus vector is a promising tool for T-cell engineering and establishing naive-like iPSCs

Jiyuan Liao¹, Yasushi Soda¹, Ai Sugawara¹, Yoshie Miura¹, Takafumi Hiramoto², Maino Tahara³, Yuto Takishima¹, Shohei Miyamoto¹, Yasuki Hijikata¹, Makoto Takeda³, Kenzaburo Tani^1,2 (1.Project Division of ALA Advanced Medical Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2.Division of Molecular and Clinical Genetics, Kyushu University, Fukuoka, Japan, 3.Department of Virology, National institute of Infectious Diseases, Tokyo, Japan)